SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gaintrader
Search This Board:
Last Post: 2/26/2015 12:15:58 PM - Followers: 159 - Board type: Free - Posts Today: 0


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

**Important: Mike Tomás' personal StemCellCEO blog!**

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:02:11 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:41 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:41 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:17 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 02/13/2015 04:01:17 PM
#13875   money flow index is up while price dropping richsean 02/26/15 12:15:58 PM
#13874   Quote LOL: "BHRT was around this price before Captain Kirk 02/26/15 10:06:59 AM
#13873   BHRT was around this price before it went EquityElite 02/26/15 07:23:36 AM
#13872   Don't even bother trying to make sense of Gsdubb 02/26/15 06:42:34 AM
#13871   You think its that bad even with MASSIVELY EquityElite 02/26/15 05:25:56 AM
#13869   Chewing through those Bid side shares. It might Captain Kirk 02/25/15 01:13:30 PM
#13868   They dropped the ask below 009? EquityElite 02/25/15 01:07:33 PM
#13867   "If the bulls fortress breaks .008 it could Captain Kirk 02/25/15 11:48:06 AM
#13866   If the bulls fortress breaks .008 it could EquityElite 02/25/15 11:33:51 AM
#13865   MM at the ASK around .009?! EquityElite 02/25/15 10:54:03 AM
#13864   Quote: "Stock manipulation of Bioheart is a serious Captain Kirk 02/25/15 10:07:56 AM
#13863   I'm new here. What wrong with this company? Thanks lovepenyland 02/25/15 07:44:31 AM
#13862   Stock manipulation of Bioheart is a serious crime. Gsdubb 02/25/15 07:24:34 AM
#13861   Someone loaded nicely today. EquityElite 02/24/15 08:48:51 PM
#13860   Those MMs are just AH! Tourbillon7575 02/24/15 05:07:44 PM
#13859   These MMs are beginning to irritate me. andyshow 02/24/15 04:21:49 PM
#13858   It looks like facts taken straight out of Auger08 02/24/15 04:11:52 PM
#13857   Are these opinions or first hand knowledge? EquityElite 02/24/15 04:09:31 PM
#13856   Quote: "What does that have to do with Captain Kirk 02/24/15 03:31:33 PM
#13855   Quote "Bid/Ask continually sliding" LOL! What does that mean??? gypsydoc 02/24/15 02:44:39 PM
#13854   This needs to hold the 8s EquityElite 02/24/15 12:41:05 PM
#13852   Bid/Ask continually sliding down again, wow: Captain Kirk 02/24/15 12:17:27 PM
#13851   LOL, Quote: "BHRT is moving in the right Captain Kirk 02/24/15 12:03:57 PM
#13850   Excellently written. Investaholic33 02/24/15 11:32:12 AM
#13849   Nothing is blind and eyes are wide open gypsydoc 02/24/15 10:55:55 AM
#13848   BMAK is parked on the Ask w/ a Captain Kirk 02/24/15 10:08:56 AM
#13846   LOL, "Good Volume, Holding very firm. The Revenue Captain Kirk 02/23/15 05:26:03 PM
#13841   Oh I'm so scared of the big bad Gsdubb 02/23/15 03:03:56 PM
#13839   I find it hard to fathom the blind Auger08 02/23/15 01:57:10 PM
#13837   LOL - Totally disagree. Did you read what gypsydoc 02/23/15 12:22:23 PM
#13836   LOL, QUOTE, "Everybody is entitled to their own Captain Kirk 02/23/15 09:47:17 AM
#13835   I've been saying that about Marvel since I Gsdubb 02/22/15 11:35:57 AM
#13834   LOL BS: "SEC filings don't lie, The CEO Captain Kirk 02/22/15 09:04:27 AM
#13829   Everybody is entitled to their own opinions, but gypsydoc 02/21/15 07:47:10 PM
#13828   That what I understood. EquityElite 02/21/15 02:40:17 PM
#13827   It's a fact. Mike Tomas and Kristin InvestorStemCell 02/21/15 02:38:22 PM
#13826   LOL BS QUOTE, "it came to $47K per Captain Kirk 02/21/15 02:12:26 PM
#13825   This is correct. He mentioned this in the andyshow 02/21/15 02:04:49 PM
#13824   Wrong again Mr. Kirk, InvestorStemCell 02/21/15 01:56:57 PM
#13823   Well if you look at apples stock when EquityElite 02/21/15 01:48:03 PM
#13822   Wrong, your the one that needs to do InvestorStemCell 02/21/15 01:40:48 PM
#13821   LOL QUOTE: "Biotech companies dilute don't mean they Captain Kirk 02/21/15 12:51:04 PM
#13820   Biotech companies dilute don't mean they go BK LOLzzz EquityElite 02/21/15 12:32:25 PM
#13818   Quote: "Ok. How much is the ACTUAL amount Captain Kirk 02/21/15 11:24:56 AM
#13817 InvestorStemCell 02/21/15 11:11:17 AM
#13816   Ok. How much is the ACTUAL amount InvestorStemCell 02/21/15 11:10:47 AM
#13815   Yep, facts are facts and opinions are BS EquityElite 02/21/15 11:10:42 AM
#13814   Gosh, completely wrong InvestorStemCell 02/21/15 11:09:40 AM
#13813   BS QUOTE, "One 100K note from December is Captain Kirk 02/21/15 11:07:36 AM
#13811   BS QUOTE "Are these opinions or facts? Looking Captain Kirk 02/21/15 10:54:34 AM